Lyell Immunopharma
Ann Tomlin is an accomplished Human Resources executive with extensive experience in the biopharmaceutical and healthcare industries. Currently serving as the Senior Vice President and Head of Human Resources at Lyell Immunopharma since July 2023, Ann previously held senior HR roles at Myovant Sciences and AbbVie, where responsibilities included leading HR through periods of significant growth and building organizations focused on innovative therapies. Ann's career began at Abbott Laboratories, where roles spanned from Director of Human Resources to Senior Manager of Talent Management. With advanced degrees in Labor and Industrial Relations and Communication, Ann has built a reputation for fostering organizational effectiveness and developing talent management processes.
Lyell Immunopharma
Lyell is an immuno-oncology company dedicated to reprogramming T cells to achieve curative therapies for solid tumors. The company takes a deliberate approach to solving what it believes to be the major barriers to successful adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies that address these barriers with T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptors (CARs).